The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. for its cGMP-compliant CHOSOURCE platform. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

XTalks

JANUARY 6, 2025

As of January 31, 2024, approximately 131 unique RNA-based therapies are in clinical development across various therapeutic areas. While these therapies span all stages of clinical development, they are particularly concentrated in earlier phases, indicating strong future growth. billion by 2031.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111